Pabinger developed a model for predicting the risk of venous thromboembolism in a patient with cancer. This can help to identify a patient who may benefit from more aggressive management. The authors are from multiple institutions in Austria, Italy, the Netherlands and Mexico.
Patient selection: patient with cancer
Outcome: cumulative 6-month incidence of venous thromboembolism
Parameters:
(1) tumor site risk
(2) plasma D-dimer in µg/mL
|
Tumor Site Risk
|
Points
|
|
low
|
0
|
|
high
|
48.2
|
|
very high
|
98.4
|
where:
• Low: breast, prostate, other
• High: lung, colorectal, esophagus, kidney, lymphoma, bladder, uterus, cervical, ovarian, sarcoma and testicular germ cell tumors
• Very high: pancreas, stomach
|
D-Dimer
|
|
|
0.1 to 8 µg/mL
|
(0.1431 * ((dimer)^3)) - (2.624 * ((dimer)^2)) + (19.65 * (dimer)) - 1.155
|
|
8 to 32
|
(0.002424 * ((dimer)^3)) - (0/1808 * ((dimer)^2)) + (5.547 * (dimer)) + 26.88
|
total score =
= SUM(points for the 2 parameters)
Interpretation:
• minimum score: 0
• maximum score: around 196
• The higher the score the greater the risk of venous thromboembolism.
cumulative 6-month incidence of VTE =
= (0.00000289 * ((score)^3)) - (0.00002721 * ((score)^2)) + (0.0417 * (score)) + 2.004
